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G-protein β3 Subunit Gene 825C/T Polymorphism   
Is Not Associated with Olanzapine-Induced Weight Gain   
in Korean Schizophrenic Patients 
 
 
 
ObjectiveaaWeight gain is a possible adverse effect of the use of antipsychotics, and is an 
important factor for long-term health and treatment compliance. Olanzapine is an atypical 
antipsychotic known to cause considerable weight gain. A relationship between weight gain 
and the G protein β3 subunit gene (GNB3) 825C/T polymorphism has been reported. We 
therefore examined this possible association in a Korean schizophrenic patient group re-
ceiving olanzapine treatment.   
MethodsaaWeight and height measurements were obtained prior to starting olanzapine and 
measured again after long-term treatment. Genotyping for the 825C/T polymorphism was 
performed using a PCR-based method.   
ResultsaaWe found that long-term treatment with olanzapine resulted in mean gains in weight 
and body mass index (BMI) of 5.2 kg and 1.93 kg/m
2, respectively. There was a no significant 
difference in the mean body weight change from baseline to the endpoint after olanzapine 
treatment between the genotype groups (p=0.796). There were also no significant differences 
in genotype or allele frequencies between the severe weight-gain (more than 10%) and minimal 
weight-gain (less than 10%) groups (χ2=0.037, p=0.98; χ2=0.020, p=0.89). 
ConclusionaaThe finding from this study thus does not support a relationship between the 
GNB3 825C/T polymorphism and weight gain in Korean schizophrenic patients receiving 
olanzapine treatment. 
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Introduction 
 
Weight gain, as a side effect from the use of atypical antipsychotics, has become a 
serious problem. More than half of those treated with these drugs will gain at least 
10% of their initial body weight over the course of therapy, and gains of more than 
40% have been reported.
1 Obesity and weight gain in adulthood are associated with 
significant health complications such as type II diabetes, coronary heart disease,
stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some
cancers.
2 Furthermore, medication-induced weight gain has been associated with a 
lower quality of life,
3,4 and is a leading barrier to continued compliance with psy-
chiatric medications.
5-7 The dibenzodiazepine-derived drugs, such as clozapine and 
olanzapine, appear to confer the greatest weight-gain liability. Most of the antipsy-
chotic-induced weight gain occurs during the first 6-8 weeks of treatment and reaches a 
plateau by the end of the first year of treatment.
8 
The underlying mechanisms by which olanzapine and other second-generation 
antipsychotics cause weight gain remain unclear; however, there are some pharma-
cological clues, such as roles for the serotonin (5-HT),
9 histamine, and adrenergic
10 
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receptors. These neurotransmitter receptors are therefore 
good candidates for an association study of antipsycho-
tic-induced obesity. Wang et al.
11 reported an association 
between the G protein β3 825C/T polymorphism and long-
term clozapine-induced weight change in a Chinese pop-
ulation. Further to this, Bishop et al.
12 recently reported a 
clinically significant relationship between GNB3 geno-
types and both negative-symptom responses and weight 
gain in schizophrenic patients treated with olanzapine. 
However, the results of that study did not reach statistical 
significance due to the small sample size. 
G proteins are important regulators of the specificity 
and temporal characteristics of cellular signaling. Heter-
otrimeric G proteins are composed of three subunits, 
which dissociate into constituent Gα and Gβγ subunits 
following receptor activation.
13 Mutations in the G-protein 
subunits may therefore contribute to changes in second 
messenger pathways.
14 Siffert et al.
15 detected a singlenu-
cleotide polymorphism (SNP) of 825C/T in exon 10 of the 
gene encoding the G-protein β3 subunit gene (GNB3). The 
Gβ3s variant has been associated with increased signal 
transduction and ion transport in the cell, and with patho-
physiological conditions such as hypertension,
15-19 obesi-
ty,
20,21 seasonality,
22 and depression.
23 In addition, Dishy et 
al.
24 reported an association between the GNB3 825C/ T 
polymorphism and weight gain during pregnancy. A pharm-
acogenetic study of sibutramine therapy showed the GNB3 
825C/T SNP to be a good predictive marker for weight 
reduction,
25 although other similar studies failed to dem-
onstrate this association.
17,26,27  
In light of the previously reported link between the 
GNB3 825C/T SNP and alterations in body weight regula-
tion,
20,28,29 we aimed to investigate the relationship between 
the GNB3 825C/T SNP and olanzapine-induced weight 
gain in Korean schizophrenic patients. 
 
Methods 
 
Subjects 
A total of 104 schizophrenic patients were enrolled 
from the three collaborating hospitals of Korea University 
Hospital. All subjects were examined by trained psychia-
trists using the Korean version of the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV),
30 leading to a diagno-
sis based on DSM-IV criteria.
31 Exclusion criteria included 
evidence of other psychiatric, medical, or neurological ill-
ness; family history of diabetes or eating disorders; and age 
over 65 or under 18 years. Application of these criteria re-
sulted in the exclusion of 25 patients. Therefore 79 patients 
were included in this study. All the subjects were ethnic 
Koreans. Some findings from these subjects have been re-
ported previously.
32-34 Written informed consents were ob-
tained, and the study protocol was approved by the Ethics 
Committee of the Korea University Hospital. 
The subjects were weighed prior to starting olanzapine 
and again after long-term treatment of at least 3 months. The 
dosage was adjusted individually according to clinical 
judgment. The use of drugs other than olanzapine was pro-
hibited. Medications such as antipsychotics, mood stabiliz-
ers, and antidepressants were avoided during the study 
due to their potential effects on weight change; however, 
we combined the use of benzodiazepines or anticholiner-
gics as needed. No subject had received olanzapine or 
clozapine prior to the present study. The mean daily dose 
of olanzapine at the end-point examination was 13.6 mg 
(SD=5.3 mg). 
Other clinical variables that were measured in the study 
were gender, age, olanzapine treatment duration and dos-
ages, and previous antipsychotics dosages (expressed as 
chlorpromazine equivalents). Changes in body weight and 
body mass index (BMI) during the treatment were also 
calculated. 
 
Genotyping 
Genomic DNA was extracted from leukocytes of the 
study subjects using a QIAamp Blood Kit (Qiagen, Ger-
many). A polymerase chain reaction (PCR)-based method 
was used for genotyping of the GNB3-gene 825C/T pol-
ymorphism.
15,23 
 
Statistical analyses 
Differences in allele frequencies between cohorts with 
different body weight changes were evaluated by a chi-
square analysis. The association of genotype with weight 
gains and changes in BMI was assessed by univariate anal-
ysis of variance (ANOVA) or Student’s t-test. All of the 
analyses were performed using standard software (SPSS for 
Windows), and probability values of p<0.05 were consid-
ered statistically significant. 
 
Results 
 
Genotype frequencies in our sample were not deviated 
from Hardy-Weinberg equilibrium (χ2=0.008, p=0.93). 
The sociodemographics, initial body weight and BMI, 
olanzapine dosage, previous antipsychotic dosages, and 
treatment duration did not differ between the genotype 
groups. There was a no significant difference in the mean 
body weight change from baseline to the endpoint after ol-
anzapine treatment between the genotype groups (p=0.796). 
When we divided the subjects into two groups, the T-allele 
carriers (the TT and CT genotypes) and the T-allele non-
carriers (the CC genotype), the mean changes in body  
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weight from baseline to endpoint after olanzapine treat-
ment were still not significantly different (p=0.515). The 
other clinical variables did not differ significantly between 
the two groups (Table 1). There were also no significant 
differences in genotype or allele frequencies between the 
severe weight-gain (more than 10%) and minimal weight-
gain (less than 10%) groups (χ 2=0.037, p=0.98; χ 2=0.020, 
p=0.89)(Table 2). 
 
Discussion 
 
One of candidate genes for an association with obe-
sity is the heterotrimeric G proteins, which are key com-
ponents of intracellular signal transduction and play a 
focal role in adipogenesis.
2,35,36 A previous study showed 
that the GNB3 825C/T variant influences lipolysis.
37 In 
the heterotrimeric G protein complex, the β subunit of the 
G protein complex is common for both Gs and Gi com-
plexes, and is ubiquitously expressed.
38 Therefore, a func-
tional variation in GNB3 may influence the action of Gs- as 
well as Gi-coupled receptors. The β1- and β2-adrenoceptors 
(Gs-coupled), and β2a-adrenoceptors  (Gi-coupled)  coexist 
in human fat cells, where they activate and inhibit li-
polysis, respectively.
37 The 825T allele of the GNB3 gene 
appears to decrease the production of GNB3 in fat cells 
and thereby inhibit lipolysis via β1-, β2-, and β2a-adreno-
ceptor signaling.
37 From a study of post-pregnancy weight 
retention, Gutersohn et al.
28 reported that subjects with 
a GNB3 825 T/T genotype are at high risk for obesity 
and post-pregnancy weight retention if they do not ex-
ercise regularly. The 825 T allele of the GNB3 gene is as-
sociated with an increased BMI across different ethnicities, 
and apparently represents a “thrifty genotype”.
20,21 Several 
studies,
20,21,28,37,39   have reported a significant relationship 
between the GNB3 825C/T polymorphism and obesity or 
fat metabolism. In contrast, Suwazono et al.
40 reported 
that the GNB3 825C/T SNP was not a significant factor in 
being overweight for 2,625 Japanese people. In addition, 
Tsai et al.
41 reported that the GNB3 825C/T SNP was not 
significant in clozapineinduced body-weight change. In 
the present study, we also did not find a sig-nificant 
association between GNB 825C/T SNP and olanzapine-
induced weight gain, which was consistent with the pre-
vious Asian studies.
40,41 It is possible that there are ethnic 
differences in the relationship between GNB3 825C/T SNP 
and obesity; however, recently, Ujike et al.
42 reported the 
825T allele of GNB3 was significantly associated with 
olanzapine-induced weight gain in 164 Japanese schizo-
phrenic patients. Very recently, Souza et al.
43 investigated 
the association of the GNB3 and antipsychotic-induced 
weight gain using meta-analytical techniques. Their analysis 
of 18,903 subjects showed no significant association al-
though there was a trend associating CC and lower BMI 
under a fixed model. Therefore, this relationship remains 
controversial.  
The major limitation of this work was that our patients 
had already received traditional antipsychotics prior to 
the study, and therefore any tendency to weight gain may 
have been triggered already. However, we observed that 
the chlorpromazine-equivalent doses of the previous an-
tipsychotics, baseline body weight, and baseline BMI did 
not differ between the genotypes. The second issue was 
that the duration of medication was not the same among 
our study cohorts, possibly influencing the results. We do 
not believe, however, that any such effect would be signif-
icant, because there was no difference in duration of olan-
TABLE 1. Demographic and clinical variables of 79 schizophrenic patients in the three genotype groups
Genotype  ANOVA  T+ vs. T-   
CC (N=22) CT  (N=39) TT  (N=18) F  p  p 
Age  042.9±11.25 49.3±11.0  045.2±12.6  02.36 0.103  0.083 
Sex (male/female) 16/6  25/14  12/6  χ2=0.48 0.788  0.508 
Previous antipsychotics (mg/day)*  765.63±492.86  0662.5±426.92  00725.0±379.65  0.322 0.726  0.505 
Baseline body weight (kg) 64.9±12.4 64.7±11.8  065.0±13.8 0.005 0.995  0.960 
Baseline BMI (kg/m2) 23.10±3.530 23.81±3.900 23.60±3.63 0.253 0.777  0.490 
Treatment duration (days) 414.36±257.20 450.6±308.8  00449.6±292.66  0.121 0.887  0.623 
Olanzapine dosage (mg/day) 14.1±4.90 13.6±5.40 14.8±4.7 0.347  0.705 0.925 
Weight change (kg) 6.18±8.66 4.88±6.32  05.26±7.15 0.228 0.796  0.515 
Weight change (%)  09.84±13.08  08.35±11.48  008.74±13.14 0.103  0.902  0.657 
BMI change (kg/m2) 2.13±2.77 1.87±2.48  01.90±2.75 0.072 0.930  0.704 
Values represent mean±SD. *Chlorpromazine equivalents. ANOVA: analysis of variance, BMI: body mass index 
 
TABLE 2. Comparison of the GNB3 genotypes and allele fre-
quencies between higher (>10%) and lower weight gain (<10%)
Genotype   Allele  frequency   
CC CT  TT      C  T   
Weight gain >10%  09 15 07  χ2=0.037  0.53 0.47  χ2=0.020 
Weight gain <10%  13  24  11  p=0.98    0.52  0.48  p=0.89 
GNB3: G-proteisn beta subunit gene 
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zapine treatment between the genotype groups, and pre-
vious studies reported that most weight gain occurred dur-
ing the first 6-8 weeks of olanzapine therapy
8 Third, we did 
not assess and control caloric intake in the subjects (in-
cluding caloric counts and meal refusals) due to the na-
ture of a long-term study. Finally, the relatively small sam-
ple size studied here limits the generality of our findings. 
Additional studies using larger sample sizes and better 
medication control are needed. It will also be necessary to 
evaluate the possible involvement of an as-yet-uncovered 
gene(s) that influence susceptibility to olanzapine-induced 
weight gain as well as the possibility of gene-gene inter-
actions. 
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